Current Issues of Pharmacy and Medical Sciences

Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis, ...

Curr Issues Pharm Med Sci., Vol. 27, No. 3, Pages 165-170

Maciej Korpysz1, Marta Morawska2, Agata Burska3, Helena Donica1

1 Department of Biochemistry Diagnostics, Medical University of Lublin

2 The Clinic of Haemato-oncology and Bone Marrow Transplantation, SPSK-1, Lublin

3 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds


DOI: 10.1515/cipms-2015-0008

Abstract

Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis, for detecting monoclonal proteins in patients with monoclonal gammopathy

Monoclonal protein (M-protein) is produced by a malignant clone of plasma cells. Detected in serum and/or urine, this typically indicates multiple myeloma (MM) or other monoclonal gammopathy (MG). In a majority of MM cases, with the production of intact monoclonal immunoglobulin (Ig), malignant plasmocytes and/or B lymphocytes often produce excessive amounts of free light chains (FLCs). Excessive synthesis of FLCs lowers the ability of renal proximal tubules to re-absorb FLCs, which results in abnormally high levels of FLCs in the urine (Bence Jones protein, BJP). In laboratory practice, there are tests available for the quantitative measurement of only FLCs κ and λ or for total light chains (TLCs). These tests measure both free forms and bound in the (Ig) molecules forms as light chains that are evident in the serum and in urine. The purpose of this study was to evaluate the FLCs and TLCs approaches in screening serum and urine samples of patients with MM, doing so in comparison to the results of immunofixation (IFE) assessment. A second purpose was to assess the suitability of the collected material for obtaining the most reliable results. The results of serum FLCs (sFLCs) assays suggest that this approach is of the highest reliability and diagnostic usefulness in the detection of MG with excess production of FLCs, in comparison to other available tests. In our work, when κ band light chains were detected in serum IFE (sIFE), 91% patients had their FLCs concentrations beyond the reference range, whereas 89% patients had increased λ FLCs when λ band light chains were detected in sIFE. We also found  abnormal sFLC κ/λ ratios in 86.4% and 88.9% of all subject patients who had κ or λ band light chains detected in their sIFE, respectively.

 

FULL TEXT

Keywords

free light chains, total light chains, monoclonal gammopathy, multiple myeloma, immunofixation

References

  1. Abraham R.S. et al.: Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin. Chem., 48, 655, 2002.
  2. Bradwell A.R. et al.: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem., 47, 673, 2001.
  3. Bradwell A.R.: Serum Free Light Chain Analysis. 6th ed. Bradwell 2010.
  4. Bradwell A.R. et al.: Serum test for assessment of patients with Bence Jones myeloma. Lancet. 361, 489, 2003.
  5. Brouwer J., Otting-van de Ruit M., Busking-van der Lely H.: Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin. Chim. Acta., 150, 267, 1985.
  6. Dispenzieri A. et al.: Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 111, 785, 2008.
  7. Dispenzieri A. et al.: Appraisal of immunoglobulin free light chain as a marker of response. Blood. 111, 4908, 2008.
  8. Herzog W., Hoffman W.: Detection of free kappa and lambda light chains in serum and urine in patients with monoclonal gammopathy. Blood 102, 5190a, 2003.
  9. Jaskowski T.D., Litwin C.M., Hill H.R.: Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin. Vaccine. Immunol., 13, 277, 2006.
  10. Jenner E: Serum free light chains in clinical laboratory diagnostics. Clin. Chim. Acta 427, 15, 2014.
  11. Katzmann J.A., Abraham R.S., Dispenzieri A.: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin. Chem., 51, 878, 2005.
  12. Katzmann J.A., Clark R.J., Abraham R.S.: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem., 48, 1437, 2002.
  13. Katzmann J.A., Kyle R.A., Benson J.: Screening panels for detection of monoclonal gammopathies. Clin. Chem., 55, 1517, 2009.
  14. Kendziorek A., Bobilewicz D.M.: Badania laboratoryjne w różnych stadiach rozwoju gammapatii monoklonalnych. In Vitro Explorer, 1, 3, 2007.
  15. Korpysz M. et al.: Concentrations of free light chains determined by nephelometry and turbidimetry. Curr. Iss. Pharm. Med. Sci. 25, 434, 2012.
  16. Korpysz M., Malecha-Jędraszek A., Donica H.: Blood serum free light chain concentration vs. Immunofixation results in patients with monoclonal gammopathy. Curr. Iss. Pharm. Med. Sci., 25, 430, 2012.
  17. Lachmann H.J. et al.: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol., 122, 78, 2003.
  18. Levinson S.S.: Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples. Clin. Chim. Acta., 412, 2206, 2011.
  19. Levinson S.S.: Urine immunofixation electrophoresis remains important and is complementary to serum free light chain. Clin. Chem. Lab. Med., 49, 1801, 2011.
  20. Levinson S.S., Keren D.F.: Free light chains of immunoglobulins: clinical laboratory analysis. Clin. Chem., 40, 1869, 1994.
  21. Mariën G. et al.: Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin. Chem., 48, 1600, 2002.
  22. Nowrousian M.R. et al.: Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin. Cancer Res., 11, 8706, 2005.
  23. Siegel D. et al.: Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies. Lab. Med., 40, 341, 2009.
  24. Singhal S. et al.: The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood, 114, 38, 2009.
  25. Snozek C.L. et al.: Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 22, 1933, 2008.
  26. Snyder M.R. et al.: Quantification of urinary light chains. Clin. Chem., 54, 1744, 2008.
  27. Sølling K. et al.: Free light chains of immunoglobulins in serum from patients with leukaemias and multiple myeloma. Scand. J. Haematol., 28, 309, 1982.
  28. Tate J.R. et al.: Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin. Chim. Acta., 376, 30, 2007.
  29. Usnarska-Zubkiewicz L., Hołojda J., Kuliczkowski K.: Serum free light chain (sFLC) – diagnostic and prognostic value in plasma cell dyscrasias. Acta Haematol. Pol., 40, 349, 2009.
  30. Van Hoeven K.H. et al.: Serum free light chain assays are more sensitive than urinary tests for free light chain monoclonal paraproteins. Clin. Chem., 55, C30a, 2009.
  31. Viedma J.A., Garrigós N., Morales S.: Comparison of the sensitivity of 2 automated immunoassays with immunofixation electrophoresis for detecting urine Bence Jones proteins. Clin. Chem., 51, 1505, 2005.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30